AG
MYOV

Aperio Group’s Myovant Sciences Ltd. MYOV Stock Holding History

Aperio Group’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,219
Closed -$11K – 2874
2019
Q2 		$11K Buy
+1,219
New +$18.2K ﹤0.01% 2776

Other funds holding MYOV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aperio Group's MYOV Position: Q3 2019 in Review

Aperio Group sold out of Myovant Sciences Ltd. (MYOV) in Q3 2019, closing a stake of 1,219 shares — an estimated $11K sold.

Aperio Group first reported a position in MYOV in Q2 2019 and held it in 1 quarter. The position peaked at $11K in Q2 2019. 65 funds tracked by Wall St. Rank hold MYOV as of Q3 2019.

  • Aperio Group reported no remaining Myovant Sciences Ltd. position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 1,219 Myovant Sciences Ltd. shares in Q3 2019, an estimated $11K.
  • Aperio Group first reported a position in Myovant Sciences Ltd. in Q2 2019 and held it in 1 quarter.
  • Aperio Group's Myovant Sciences Ltd. position peaked at $11K in Q2 2019.
  • 65 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.